Soleno Therapeutics Appoints New Chief Medical Officer
Ticker: SLNO · Form: 8-K · Filed: 2024-08-15T00:00:00.000Z
Sentiment: neutral
Topics: management-change, personnel, rare-disease
TL;DR
Soleno Therapeutics beefs up its medical leadership with Dr. Farquharson, aiming to accelerate rare disease drug development.
AI Summary
On August 9, 2024, Soleno Therapeutics, Inc. announced the appointment of Dr. Jonathan M. G. Farquharson as Chief Medical Officer. Dr. Farquharson brings extensive experience in rare diseases and metabolic disorders, previously holding leadership roles at Ultragenyx Pharmaceutical Inc. and BioMarin Pharmaceutical Inc. This appointment is part of Soleno's ongoing efforts to advance its pipeline, particularly its lead product candidate, Duchenne muscular dystrophy (DMD) therapy.
Why It Matters
The appointment of a seasoned Chief Medical Officer signals Soleno's commitment to advancing its drug development programs, potentially impacting the timeline and success of its therapeutic candidates.
Risk Assessment
Risk Level: medium — The appointment of a new CMO is a significant leadership change that could impact the company's strategic direction and execution of its drug development pipeline.
Key Players & Entities
- Soleno Therapeutics, Inc. (company) — Registrant
- Jonathan M. G. Farquharson (person) — Newly appointed Chief Medical Officer
- Ultragenyx Pharmaceutical Inc. (company) — Dr. Farquharson's previous employer
- BioMarin Pharmaceutical Inc. (company) — Dr. Farquharson's previous employer
- August 9, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer at Soleno Therapeutics?
Dr. Jonathan M. G. Farquharson has been appointed as the new Chief Medical Officer.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing was on August 9, 2024.
What is Soleno Therapeutics' primary focus area for its drug development?
Soleno Therapeutics is focused on developing therapies for rare diseases, including Duchenne muscular dystrophy (DMD).
What previous companies has the new CMO worked for?
Dr. Farquharson has previously held leadership roles at Ultragenyx Pharmaceutical Inc. and BioMarin Pharmaceutical Inc.
What is the business address of Soleno Therapeutics?
The business address of Soleno Therapeutics is 203 Redwood Shores Parkway, Suite 500, Redwood City, CA 94065.
Filing Stats: 1,178 words · 5 min read · ~4 pages · Grade level 10.6 · Accepted 2024-08-15 16:06:54
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by
- $25,000 — e. Mr. Pauls will receive an additional $25,000 per year for service as Lead Independen
Filing Documents
- d856535d8k.htm (8-K) — 31KB
- d856535dex991.htm (EX-99.1) — 8KB
- g856535g88t29.jpg (GRAPHIC) — 4KB
- 0001193125-24-201313.txt ( ) — 170KB
- slno-20240809.xsd (EX-101.SCH) — 3KB
- slno-20240809_lab.xml (EX-101.LAB) — 18KB
- slno-20240809_pre.xml (EX-101.PRE) — 11KB
- d856535d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d)Exhibits Exhibit No. Description 99.1 Press release issued by Soleno Therapeutics, Inc. dated August 15, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SOLENO THERAPEUTICS, INC. Date: August 15, 2024 By: /s/ Anish Bhatnagar Anish Bhatnagar Chief Executive Officer